Profile data is unavailable for this security.
About the company
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).
- Revenue in USD (TTM)9.94m
- Net income in USD-164.57m
- Incorporated2011
- Employees68.00
- LocationSyros Pharmaceuticals Inc35 Cambridge Park DriveCAMBRIDGE 02140United StatesUSA
- Phone+1 (617) 744-1340
- Fax+1 (617) 744-1377
- Websitehttps://syros.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coya Therapeutics Inc | 6.00m | -7.99m | 128.21m | 8.00 | -- | 3.55 | -- | 21.36 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| FitLife Brands Inc | 52.70m | 5.30m | 129.21m | 37.00 | 25.99 | 4.78 | 23.97 | 2.45 | 1.08 | 1.08 | 10.74 | 5.88 | 1.30 | 3.44 | 38.31 | 1,424,297.00 | 13.07 | 26.40 | 15.94 | 33.92 | 40.67 | 42.09 | 10.05 | 17.65 | 0.5419 | 16.81 | 0.4253 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Aeon Biopharma Inc | 0.00 | -36.63m | 130.31m | 10.00 | -- | -- | -- | -- | -0.9859 | -0.9859 | 0.00 | -4.12 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.0045 | -- | -- | -- | -- | 30.30 | -- | -- | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 131.48m | 53.00 | 8.47 | 2.83 | 7.78 | 2.78 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Vaxart Inc | 7.38m | -82.47m | 132.45m | 109.00 | -- | 1.99 | -- | 17.95 | -0.5844 | -0.5844 | 0.0519 | 0.3767 | 0.0601 | -- | 4.87 | 67,697.25 | -67.13 | -49.60 | -77.06 | -54.86 | -- | -- | -1,117.56 | -1,398.00 | -- | -- | 0.10 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Amylyx Pharmaceuticals Inc | 380.79m | 49.27m | 136.01m | 384.00 | 2.84 | 0.3124 | 2.70 | 0.3572 | 0.7045 | 0.7045 | 5.43 | 6.40 | 0.8379 | 1.06 | 13.76 | 991,630.20 | 10.84 | -- | 12.63 | -- | 93.32 | -- | 12.94 | -- | 5.20 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| PDS Biotechnology Corp | 0.00 | -42.94m | 136.81m | 25.00 | -- | 4.72 | -- | -- | -1.39 | -1.39 | 0.00 | 0.7896 | 0.00 | -- | -- | 0.00 | -62.97 | -51.63 | -76.04 | -59.00 | -- | -- | -- | -- | -- | -33.04 | 0.4772 | -- | -- | -- | -5.11 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -51.69m | 138.08m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 9.94m | -164.57m | 138.99m | 68.00 | -- | 8.25 | -- | 13.99 | -5.77 | -5.77 | 0.3508 | 0.63 | 0.0482 | -- | 11.73 | 146,102.90 | -79.76 | -54.44 | -95.35 | -64.32 | -- | -- | -1,656.51 | -772.82 | -- | -- | 0.7122 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Scilex Holding Co | 46.74m | -166.98m | 141.00m | 105.00 | -- | -- | -- | 3.02 | -1.25 | -1.25 | 0.3587 | -1.73 | 0.4977 | 5.61 | 1.67 | 445,171.40 | -121.73 | -- | -- | -- | 66.45 | -- | -244.59 | -- | 0.17 | -11.86 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Repare Therapeutics Inc | 51.13m | -93.80m | 141.31m | 179.00 | -- | 0.6662 | -- | 2.76 | -2.23 | -2.23 | 1.21 | 5.03 | 0.1655 | -- | 5.21 | 285,659.20 | -30.36 | -23.40 | -37.50 | -26.37 | -- | -- | -183.44 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Sagimet Biosciences Inc | 2.00m | -27.88m | 142.02m | 10.00 | -- | 1.12 | -- | 71.01 | -1.31 | -1.31 | 0.0937 | 3.98 | -- | -- | -- | 200,000.00 | -- | -- | -- | -- | -- | -- | -1,393.80 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| I-Mab ADR | 3.82m | -202.44m | 142.44m | 220.00 | -- | 0.6002 | -- | 37.31 | -2.43 | -2.43 | 0.0459 | 2.94 | 0.0083 | -- | -- | 17,355.36 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Biostem Technologies Inc | 16.69m | -7.86m | 145.77m | 67.00 | -- | -- | -- | 8.74 | -0.5699 | -0.5699 | 1.21 | -0.0607 | -- | -- | -- | -- | -- | -- | -- | -- | 92.44 | -- | -47.12 | -- | 0.7825 | -10.22 | 1.26 | -- | -- | -- | -- | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Syros Pharmaceuticals Inc's reporting currency: US Dollar USD
39.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 31 Dec 2023 | 2.51m | 9.63% |
| Adage Capital Management LPas of 31 Dec 2023 | 2.07m | 7.97% |
| Avidity Partners Management LPas of 31 Dec 2023 | 1.67m | 6.44% |
| Point72 Asset Management LPas of 31 Dec 2023 | 1.47m | 5.66% |
| Deep Track Capital LPas of 31 Dec 2023 | 828.49k | 3.19% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 761.04k | 2.93% |
| Opaleye Management, Inc.as of 31 Dec 2023 | 359.37k | 1.38% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 241.31k | 0.93% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 239.68k | 0.92% |
| DAFNA Capital Management LLCas of 31 Dec 2023 | 214.89k | 0.83% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
